SomnoMed’s oral device for sleep apnea is gaining traction across Europe and making inroads in the US market, reports ProactiveInvestors Australia.

Perhaps missed by many investors is that now all of Northern, Central and Southern Europe are covered by SomnoMed to market and sell its oral devices – providing a strong beach-head to increase sales of its Continuous Open Airway Therapy (COAT) products.

The outlook for European sales volume and revenue growth in FY14/15 is strong. With gross margins of 67%, this provides the engine for strong growth in operating income after cost of goods sold.